Regulatory Developments On Pharmaceutical Intellectual Property Rights
This article was originally published in PharmAsia News
China Intellectual Property News published an article introducing the laws and regulations on intellectual property rights for pharmaceuticals. Related laws cover patent, trademark, drug administration and anti-trust competition. Reviews are provided on regulatory provisions for new drugs approvals, protection of new medicines and technology transfer, administrative protection of pharmaceuticals, drug registration, and protection of TCM. The overview summarized the protection of pharmaceuticals from different aspects-protection terms, major content and newly revised items after China's entry to the World Trade Organization. Last year, the country ratified an amended version of WTO's Agreement of the Trade-Related Aspects of Intellectual Property Rights, which attempts to strike a balance between IPRs and public health. (Click here for more - Chinese Language)
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.